« Return to News | Awards & Advancement

Attunity appoints Lawrence Schwartz as marketing vice president

Wednesday, June 26, 2013 03:17 PM

Attunity, a provider of information availability software solutions, has appointed Lawrence Schwartz as the company’s vice president of marketing. Schwartz will be responsible for marketing and sales enablement. He will focus on driving demand generation and brand awareness as the company positions itself for growth in the data replication and cloud computing markets. Schwartz joins Attunity with 20 years of experience in data and information systems.

Schwartz previously was vice president of marketing for Tokutek, a database technology company. At Tokutek, Schwartz led worldwide marketing, PR, product management, social, community and partner efforts for MySQL and MongoDB solutions at the forefront of Big Data.

Schwartz also held senior marketing and product management roles at E Ink, a pioneer of TFT and electronic paper displays for the eBook and tablet markets. Schwartz was at EMC in the Symmetrix division, where he managed the marketing rollout of flash storage as well as led the introduction of RSA security features into the product line.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.